Diane Bouis, PhD MBA

BioMEMS Diagnostics is developing an ultrahigh performance Point of Care and at-home diagnostics platform featuring a simple, single-use test cartridge, handheld analyzer and smart device app to deliver results for complex tests previously available only in hospital or central lab settings. Up to ten different tests can be integrated into a single cartridge with results in less than 5 minutes. Test panels currently in development include respiratory infections, systemic inflammation, healthy aging, drug-resistant UTI, tropical diseases, recurrent myocardial infarction and concussion, many of which use a saliva or urine sample instead of a blood draw -- vastly increasing access to high-need, high-complexity testing at home or at Point of Care. The BioMEMS technology features a hybrid biosensor array that can be configured to accept a broad range of antibodies, aptamers, nucleic probes and other affinity agents, able to detect most any biomarker, ranging from a single pathogen to a single protein in most any biofluid. This is disruptive technology that also crushes the cost of manufacturing chip-based diagnostics by producing "blank" cartridges in the millions, and then adding the chemistry for specific diagnostics targets in a secondary operation, exponentially lowering costs. In so doing, BioMEMS vastly increases access to high-performance, high-complexity testing, offering an accurate, affordable testing platform with the potential to displace the current paradigm of collecting samples, transporting to a remote lab, and waiting for results when sophisticated tests are needed. No skill, no lab required. This proprietary, patent-pending, digital testing platform is equally effective in a doctors office as it is in an ambulance, a combat zone or a tent hospital in South Sudan. A disruptive technology capable of transforming point-of-care. point-of-need and at home diagnostics.

Culturewells cleanliness insights platform helps administrators learn exactly which germs are growing in their facilities, the riskiness of those germs, and provides actionable recommendations to improve cleaning processes. In healthcare, we reduce costly healthcare-associated infections (HAIs) through our subscription-based sampling, testing, germ risk profiles, and remediation recommendations.

Ben Franklin Technology Partners is Pennsylvania’s statewide innovation engine and one of the nation’s most respected high-tech investment models. Since 1983, we have fueled emerging technology ventures, strengthened established manufacturers, and accelerated economic growth across the state. With four regional offices: Central and Northern PA, Northeastern PA, Southeastern PA, and Innovation Works in Southwestern PA, we combine statewide reach with local expertise. Together, we provide strategic investments, hands-on support, and industry connections that transform ideas into thriving enterprises. Our impact speaks for itself: more than 159,000 jobs created and 30 billion dollars in economic growth. By backing the high-risk companies others will not, we ensure Pennsylvania remains competitive, prosperous, and positioned to lead in the global innovation economy. The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority. Follow us as we help light the way for Pennsylvania’s innovators, manufacturers, and job creators.

BioMEMS Diagnostics is developing an ultrahigh performance Point of Care and at-home diagnostics platform featuring a simple, single-use test cartridge, handheld analyzer and smart device app to deliver results for complex tests previously available only in hospital or central lab settings. Up to ten different tests can be integrated into a single cartridge with results in less than 5 minutes. Test panels currently in development include respiratory infections, systemic inflammation, healthy aging, drug-resistant UTI, tropical diseases, recurrent myocardial infarction and concussion, many of which use a saliva or urine sample instead of a blood draw -- vastly increasing access to high-need, high-complexity testing at home or at Point of Care. The BioMEMS technology features a hybrid biosensor array that can be configured to accept a broad range of antibodies, aptamers, nucleic probes and other affinity agents, able to detect most any biomarker, ranging from a single pathogen to a single protein in most any biofluid. This is disruptive technology that also crushes the cost of manufacturing chip-based diagnostics by producing "blank" cartridges in the millions, and then adding the chemistry for specific diagnostics targets in a secondary operation, exponentially lowering costs. In so doing, BioMEMS vastly increases access to high-performance, high-complexity testing, offering an accurate, affordable testing platform with the potential to displace the current paradigm of collecting samples, transporting to a remote lab, and waiting for results when sophisticated tests are needed. No skill, no lab required. This proprietary, patent-pending, digital testing platform is equally effective in a doctors office as it is in an ambulance, a combat zone or a tent hospital in South Sudan. A disruptive technology capable of transforming point-of-care. point-of-need and at home diagnostics.

Researchers and physicians can now quantify: Capillary density Capillary blood volume Blood flow and red cell velocity Endothelial glycocalyx function GlycoCheck measures and analyzes microvascular health, and objectively reports a MicroVascular Health Score (MVHS). Lower scores are linked to: Diabetes Hypertension Heart Disease Kidney Disease Stroke Dementia Septic Shock Inflammatory Disorders Compromised Immunity Cancer Metastasis

We believe that innovation can change the world for good, and we’re providing the tools that empower innovators & entrepreneurs to bring their ideas to life.

Culturewells cleanliness insights platform helps administrators learn exactly which germs are growing in their facilities, the riskiness of those germs, and provides actionable recommendations to improve cleaning processes. In healthcare, we reduce costly healthcare-associated infections (HAIs) through our subscription-based sampling, testing, germ risk profiles, and remediation recommendations.